Navigation Links
Shire plc: IFRS Results for the Year Ending December 31, 2007
Date:3/25/2008

ion). Amortisation charges, including the amortisation on acquired products, were US$147.3 million for the year to December 31, 2007 (2006: US$81.5 million), the increased charge is primarily due to the amortisation of DAYTRANA, ELAPRASE, DYNEPO and VYVANSE intangible assets following the product launches in June 2006, August 2006, March 2007 and July 2007 respectively.

Intangible asset impairment charges within SG&A for the year to December 31, 2007 were US$0.4 million (2006: US$1.1 million). Impairment charges relating to goodwill for the year to December 31, 2007 were US$133.7 million (2006: US$271.9 million) related to the goodwill arising on the acquisition of BioChem Pharma Inc. Depreciation, amortisation and impairment charges also include an adjustment to goodwill of US$11.0 million (2006: US$nil) in respect of the prior year acquisition of TKT.

For the year to December 31, 2007 SG&A included a charge of US$51.7 million for share based compensation (2006: US$14.6 million), which included a US$22.5 million cumulative catch up charge (2006: US$nil) in respect of 2005 option awards.

The catch-up charge relates to options issued by Shire in 2005 under the 2000 Executive Scheme. This charge arises as a result of the strong growth in revenue and profits (as determined under US GAAP) which the Group generated in the fourth quarter of 2007. This growth has in turn caused the Group to revise its original assumptions on which the IFRS 2 charge was based.

Gain on sale of product rights

For the year to December 31, 2007 Shire recognised gains of US$102.9 million on the sale of non-core products.

Shire received US$209.6 million (net of transaction costs of US$2.2 million) from Laboratorios Almirall S.A. ("Almirall") for a portfolio of non core products comprising the dermatology products SOLARAZE and VANIQA and six non-promoted products across a range of indications, which were sold by Shire primarily in the UK, France, Germany,
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
2. Shire plc: Correction Re Website
3. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
4. Shire Engages Palio
5. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
6. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
7. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
8. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
9. Shire plc: Board Changes
10. David Mott Appointed Non Executive Director at Shire
11. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014   TRU-D SmartUVC LLC and its UK ... automated disinfection robot, TRU-D SmartUVC, at FIS 2014 in ... to 26 at Stand 23. The conference, hosted ... Kingdom,s largest infection-related event of its kind and ... of the leading events of its type throughout the world. ...
(Date:11/21/2014)... November 20, 2014 The ... Chassis, Oligos, Enzymes, Cloning kits), Technology (Bioinformatics, ... (Biofuels, Pharmaceuticals, Biomaterials, Bioremediation) - Global Forecast ... market drivers, threats, opportunities, and challenges. , ... figures spread through 185 pages and in-depth ...
(Date:11/21/2014)... 2014 Deep Research Report on ... research report on the transformer market. The report ... and industry chain structure as well as industry ... including China’s domestic market as well as global ... analysis. The report also covers information on policy, ...
(Date:11/18/2014)... , Nov. 18, 2014 Cord Blood ... sponsor of the 10th Annual World Stem Cell Summit, the ... stakeholders. The 2014 World Stem Cell Summit will be held ... Antonio, Texas . The World ... development of lifesaving cures and therapies, convening the most prominent ...
Breaking Biology Technology:TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 2TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 4International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 2International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 3Cord Blood Registry Sponsors 2014 World Stem Cell Summit 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 3
... genetics (Nasdaq: DCGN ) announced today that it ... institution, pursuant to which NBI has purchased deCODE,s auction rate ... the agreement, deCODE has the call option to require NBI ... time prior to December 31, 2009. NBI has the put ...
... MISSISSAUGA, ON, Jan. 20 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ: ... a Nasdaq Staff Deficiency Letter on January 13, 2009, ... director requirement as set forth in Nasdaq Marketplace Rule ... the resignation of a Director, which was announced publicly ...
... Inc. (Nasdaq: NLTX ), today announced that ... natriuretic peptide franchise, including CD-NP which is in Phase ... is a pre-clinical compound. Nile will suspend the further ... compound to Dr. Cesare Casagrande. "We are disappointed that ...
Cached Biology Technology:deCODE Sells Auction Rate Securities 2deCODE Sells Auction Rate Securities 3Vasogen Complies with NASDAQ Marketplace Rule 4350(c)(1) 2Nile Therapeutics Announces Focus on CD-NP for Acute Heart Failure and Termination of 2NTX-99 Program 2Nile Therapeutics Announces Focus on CD-NP for Acute Heart Failure and Termination of 2NTX-99 Program 3Nile Therapeutics Announces Focus on CD-NP for Acute Heart Failure and Termination of 2NTX-99 Program 4
(Date:11/7/2014)... -- Leading Biometric companies aim to provide consumers ... transactions.  Companies in focus today are: NXT-ID, Inc. (NASDAQ: ... ), Google Inc. (NASDAQ: GOOG ), Microsoft Corporation ... EBAY ) and MasterCard Inc. (NYSE: MA) NXT-ID, ... authentication company focused on the growing mobile commerce is pleased ...
(Date:11/6/2014)... cancer deaths occur because of metastasis, yet progress ... been slow. , "It,s been particularly challenging to ... Gujral, research fellow in systems biology at Harvard ... detected until after they,ve already metastasized." , Gujral ... that should help researchers better understand how metastasis ...
(Date:11/6/2014)... Medicine, Inc, a Baltimore-based bioinformatics company focused on ... a research collaboration with the international leader in ... CSBR). , "There are many companies utilizing advances ... TumorGraft technology is unique in a way that ... vast amounts of valuable data. Our bioinformatic analysis ...
Breaking Biology News(10 mins):Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6Migration negation 2Migration negation 3Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2
... nurses, and firefighters essential during a severe pandemic influenza ... and utility workers. That,s the conclusion of a Johns ... of Biosecurity and Bioterrorism . The report, led ... for the Johns Hopkins Berman Institute of Bioethics, provides ...
... neuroblastoma and melanoma developed by scientists and ... collaboration with investigators from the University of Iowa is ... to new research published in the October edition of ... vaccine uses the tumor,s own protein to induce an ...
... fossils revealed a herd of dinosaurs that perished in ... are characterized by a bony frill on the back ... had large bony structures above their nose and eyes ... structures probably supported horns of keratin. According to ...
Cached Biology News:Rethinking who should be considered 'essential' during a pandemic flu outbreak 2Children's National researchers develop novel anti-tumor vaccine 2A new dinosaur species, Pachyrhinosaur lakustai, unveiled from Pipestone Creek, Alberta, Canada 2
IHC Polymer Detection Kit (Rabbit DAB)150 slides...
... Desselberger (1995) • This book is ... classical and molecular techniques currently used ... and analysis of virus-specific antibodies and ... presented covering immunoassays, blotting and hybridization ...
Performance, mycoplasma, virus, and endotoxin tested. Collected from calves 14 days old or less...
Bovine Serum...
Biology Products: